An unresolved question regarding tissue-engineered (TE) cardiac valves and vessels is the fate of the transplanted cells in vivo. We have developed a strategy to track the anatomic location of seeded cells within TE constructs and neighboring tissues using a retroviral vector system encoding green and red fluorescent proteins (GFPs and RFPs, respectively) in ovine circulating endothelial progenitor cells (EPCs) and bone marrow–derived mesenchymal stem cells (BMSCs). We demonstrate that stable transduction ex vivowith high-titer Moloney murine leukemia virus–based retroviral vector yields transduction efficiency of greater than 97 GFPEPC– and RFPmesenchymal stem cell (MSC)-derived cells. Cellular phenotype and transgene expression were also maintained through 25 subsequent passages. Using a retroviral vector system to distinguish our pre-seeded cells from tissue-resident progenitor cells and circulating endothelial and marrow-derived precursors, we simultaneously co-seeded 2 × 106GFPEPCs and 2 × 105RFPMSCs onto the TE patches. In a series of ovine pulmonary artery patch augmentation studies, transplanted GFPEPC– and RFPMSC-derived cells persisted within the TE patch 7 to 14 days after implantation, as identified using immunofluorescence. Analysis showed 81 luminal coverage of the TE patches before implantation with transduced cells, increasing to 96 at day 7 and decreasing to 67 at day 14 post-implantation. This suggests a temporal association between retroviral expression of progenitor cells and mediating effects of these cells on the physiological remodeling and maturation of the TE constructs. To our knowledge, this is the first cardiovascular tissue-engineering in vivostudy using a double-labeling method to demonstrate a direct evidence of the source, persistence, and incorporation into a TE vascular patch of co-cultured and simultaneously pre-seeded adult progenitor cells. [ABSTRACT FROM AUTHOR]